Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
procaterol + montelukast
- Development stage
- Unknown
- Lead developer
- Beijing Children's Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Procaterol + montelukast is a combination therapy consisting of a selective beta-2 adrenergic receptor agonist and a leukotriene receptor antagonist. Procaterol acts as a bronchodilator by stimulating beta-2 receptors in the airway smooth muscle, while montelukast inhibits the cysteinyl leukotriene receptor 1 (CysLT1), reducing inflammation and bronchoconstriction. This combination is particularly studied in the pediatric population for the treatment of cough variant asthma (CVA), where it has shown efficacy in reducing cough frequency and improving lung function. Research conducted by institutions like Beijing Children’s Hospital and Capital Medical University has highlighted its role in managing CVA in children, addressing both the bronchospastic and inflammatory components of the disease.
- Other names
- procaterol hydrochloride + montelukast sodium
02
Targets
CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)ADRB2 (β2)LTB4R2 (Leukotriene B4 receptor 2)CYSLTR2 (Cysteinyl leukotriene receptor 2)
Beyond the preview
Go deeper on procaterol + montelukast.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on procaterol + montelukast.